ClinicalTrials.gg
Active, not recruitingNCT06471010B-DITUpdated Oct 20, 2026

B-DIT Feasibility Study

An observational study in Personality Disorders, sponsored by De Viersprong. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by De Viersprong · Observational

How we know

Updated Oct 20, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
27
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Personality Disorders with a site in Netherlands — 4 open to participants now, 5 under way, none of them phase 3. Personality Disorders · Netherlands.

Started
2024
with 3 others
Observational
2 of 10
1 open now
Registered
7th of 10
by date
Lead sponsor
1 of 10
De Viersprong

Among the 10 studies in Personality Disorders with a site in Netherlands, this one is one of 4 that started in 2024, is one of 2 observational ones, and was the 7th registered.

Personality Disorders

127 studies on the registry are indexed under Personality Disorders; 25 are open to participants now.

Browse Personality Disorders studies →

Open to participants now

4 of the 10 studies in Personality Disorders with a site in Netherlands are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 19 Personality Disorders studies recruiting now, 14 (74%) set no upper age limit and 5 (26%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Personality Disorders with a site in Netherlands, or all of them as a file.
02

Study summary

This study aims to explore the feasibility, acceptability, and effectiveness of a new blended psychotherapeutic treatment program based on Dynamic Interpersonal Therapy (B-DIT) for adult clients with personality pathology. Blended interventions have the potential to improve treatment accessibility and cost-effectiveness for individuals with personality pathology and promote a sense of agency and ownership among clients regarding their treatment as compared to traditional Face-to-Face (FTF) approaches. This may improve treatment outcome and recovery.

The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp, integrates FTF therapy and online modules into a cohesive treatment program. The program spans three phases: an individual phase lasting approximately two months, followed by a four-month group phase, and concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases.

The primary study aims are (1) to monitor and evaluate the feasibility of B-DIT; which includes evaluating client satisfaction, treatment drop-out rates, user parameters related to online modules, and an interview-based qualitative analysis of therapists' and clients' experiences; and (2) to gather initial effectiveness data based on Routine Outcome Monitoring (ROM) measurements, complemented by a Single Case Experimental Design (SCED). The research questions are as follows:

  1. How acceptable is the blended treatment program, B-DIT, for adult clients with personality pathology and their therapists?
  2. What is the effectiveness of B-DIT for adult clients with personality pathology in terms of progress in reducing symptom burden, overall functioning, and personality functioning, including changes in process measures such as mentalizing ability, epistemic trust, and agency?
  3. Exploratively, the effects on these process and outcome measures across treatment phases will be compared to ascertain if observed changes align with the presumed working mechanisms of the intervention.
Read the detailed description

This study aims to explore the feasibility, acceptability, and effectiveness of a new blended psychotherapeutic treatment program based on Dynamic Interpersonal Therapy (B-DIT) for adult clients with personality pathology. B-DIT integrates face-to-face (FTF) therapy and online modules into a cohesive treatment program, offering potential advantages in terms of treatment accessibility and cost-effectiveness for individuals with personality pathology. Additionally, blended interventions may have added value compared to traditional FTF approaches by fostering a greater sense of agency and ownership among clients regarding their treatment. While e-health and blended interventions have demonstrated promising treatment outcomes across various mental health areas, there is limited evidence for interventions targeting personality pathology.

B-DIT, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp, addresses this gap and provides a blended intervention for clients with mild to moderately severe personality pathology. The program spans three phases: an individual phase lasting approximately two months, followed by a four-month group phase, and concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases.

The primary study aims are (1) to monitor and evaluate the feasibility of B-DIT; which includes evaluating client satisfaction, treatment drop-out rates, user parameters related to online modules, and conducting a qualitative analysis of therapists' and clients' experiences; and (2) to gather initial effectiveness data based on Routine Outcome Monitoring (ROM) measurements, complemented by a Single Case Experimental Design (SCED). The SCED allows drawing conclusions about effectiveness based on a relatively small sample, while accommodating potential refinements to the intervention during the study period. The following research questions will be addressed:

  1. How acceptable is a blended treatment program, Dynamic Interpersonal Therapy (B-DIT), for adult clients with personality pathology and for their therapists?
  2. How effective is B-DIT for adult clients with personality pathology in terms of progress in improving symptom burden, overall functioning, and personality functioning, along with changes in process measures (mentalizing ability, epistemic trust, agency)?
  3. Exploratively, the effects on these process and outcome measures across treatment phases will be compared to determine if observed changes are consistent with the presumed working mechanisms of the intervention.

Participants in the study will receive care as usual. In complement to regular Routine Outcome Monitoring assessments as integrated part of treatment, participants will be asked to complete an additional 26-item questionnaire repeatedly during their treatment and over a one year follow-up period in a Single Case Experimental Design with four phases:

Phase A - Baseline Waiting List (before start of treatment) - with a minimum of 3 weeks; Phase B - Intensive treatment phase (10 weeks of individual treatment followed by 30 weeks of group treatment) - 30 weeks; Phase C - Booster treatment phase - 16 weeks; Phase D - Follow-up phase after the end of treatment - 12 months.

The (impact of) expectations with regards to their treatment will be assessed at baseline and at end of treatment. Clients and clinicians will be questioned about their experiences in the treatment program (at the end of treatment) by means of semi-structured qualitative interviews.

03

Conditions studied

  • Personality Disorders

Browse trials for

Keywords

  • Blended treatment
  • E-health
  • Psychotherapy
  • Personality disorder
  • Personality pathology
  • Treatment accessibility
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Clients referred to De Viersprong are eligible for B-DIT when they exhibit mild to moderately severe impairments in personality functioning (including both cluster B, C, or a mixed presentation within unspecified personality disorder). Clients typically present with persistent problems in specific areas of their functioning, and typically have had previous, unsuccessful treatments. Adequate functioning in at least one domain of life (such as family, work, other societal roles) should be ensured, which allows for the generalization of treatment gains during and after the relatively short-term/ low intensity intervention.

All patients that are referred to B-DIT at de Viersprong are eligible for the study.

Eligibility criteria

Inclusion criteria for treatment referral:

  1. 18 years of age or older
  2. mild to moderately severe impairments in personality functioning, including both cluster B and cluster C personality problems as well as a mixed presentation within unspecified personality disorder.

General exclusion criteria for treatment at the Viersprong:

  1. insufficient proficiency in the Dutch language
  2. no permanent place of residence
  3. intellectual disability (IQ \< 80)
  4. organic brain disorder
  5. autism spectrum disorders
  6. schizophrenia or schizophreniform disorder
  7. (untreated) eating disorder, extreme obesity, or a \< 17.5
  8. (untreated) addiction.

Additional exclusion criteria for the B-DIT treatment:

  1. acute risk of crisis requiring stabilizing/crisis interventions
  2. Severe PTSD or the severe range of personality problems (structural: low-level borderline organization).

There are no additional inclusion/exclusion criteria for participation in the study, other than those that apply to treatment.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
27 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Groups and cohorts

  • B-DIT

    Other: Blended Dynamic Interpersonal Therapy (B-DIT)

Interventions

  • OtherBlended Dynamic Interpersonal Therapy (B-DIT)

    The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp (http://www.onlinepsyhulp.be), integrates FTF therapy and online modules into a cohesive treatment program for clients with personality pathology. Both FTF and online treatment components are anchored in the Dynamic Interpersonal Therapy (DIT) framework (Lemma et al., 2011).The program spans three phases: an individual phase lasting approximately two months, followed by a five-month group phase, concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases. Both verbal psychotherapy and art therapy are offered as treatment modalities in the face-to-face treatment sessions. The program is implemented by a multidisciplinary team.

06

What researchers measure

Primary outcomes

  1. Personality functioning- Severity Indices of Personality Functioning

    Personality functioning- Severity Indices of Personality Functioning (SIPP-60): a 60-item self-report ROM questionnaire Administered as part of Routine Outcome Monitoring at start of intervention and subsequently every treatment evaluation (at 12, 20 and 30 weeks after start of the intervention); at the end of treatment; and at two follow-up timepoints after the end of treatment (6 and 12 months follow-up)

    Time frame: From baseline, throughout the intervention, to 12 months after end of treatment

  2. Personality functioning- Level of Personality Functioning

    Personality functioning - Level of Personality Functioning Brief-Form 2.0 (LBFS-BF-2.0): a 12-item self-report ROM questionnaire. Administered as part of Routine Outcome Monitoring at start of intervention and subsequently every treatment evaluation (at 12, 20 and 30 weeks after start of the intervention); at the end of treatment; and at two follow-up timepoints after the end of treatment (6 and 12 months follow-up).

    Time frame: From baseline, throughout the intervention, to 12 months after end of treatment

  3. Symptom distress

    Brief Symptom Inventory (BSI): a 53-item self-report ROM questionnaire. Administered as part of Routine Outcome Monitoring at start of intervention and subsequently every treatment evaluation (at 12, 20 and 30 weeks after start of the intervention); at the end of treatment; and at two follow-up timepoints after the end of treatment (6 and 12 months follow-up)

    Time frame: From baseline, throughout the intervention, to 12 months after end of treatment

  4. Overall functioning

    Outcome Rating Scale (ORS): a 4-item self-report questionnaire. Outcome measures of the Single Case Experimental Design are assessed using a composite questionnaire that is delivered to participants repeatedly in varying frequencies depending on the phase of treatment and respective phase of the SCED. During: * Phase A: weekly during the baseline waiting period with a minimum of three weeks. * Phase B: bi-weekly during the first intervention phase of 10 weeks individual treatment and second intervention phase of 20 weeks group treatment * Phase C: monthly during the third intervention phase (booster phase) of 16 weeks * Phase D: two-monthly during the follow-up phase of 12 months

    Time frame: From baseline, throughout the intervention, to 12 months after end of treatment

  5. Usability of the online portal

    System Usability Scale (SUS): a 10-item self-report questionnaire

    Time frame: End of treatment (end of phase C)

Secondary outcomes

  1. Agency

    General Self-Efficacy Scale (GSES): a 10 item self-report questionnaire Outcome measures of the Single Case Experimental Design are assessed using a composite questionnaire that is delivered to participants repeatedly in varying frequencies depending on the phase of treatment and respective phase of the SCED. * Phase A: weekly during the baseline waiting period with a minimum of three weeks. * Phase B: bi-weekly during the first intervention phase of 10 weeks individual treatment and second intervention phase of 20 weeks group treatment * Phase C: monthly during the third intervention phase (booster phase) of 16 weeks * Phase D: two-monthly during the follow-up phase of 12 months

    Time frame: From baseline, throughout the intervention, to 12 months after end of treatment

  2. Epistemic Trust

    4 selected items of the Questionnaire Epistemic Trust (QET) Outcome measures of the Single Case Experimental Design are assessed using a composite questionnaire that is delivered to participants repeatedly in varying frequencies depending on the phase of treatment and respective phase of the SCED. * Phase A: weekly during the baseline waiting period with a minimum of three weeks. * Phase B: bi-weekly during the first intervention phase of 10 weeks individual treatment and second intervention phase of 20 weeks group treatment * Phase C: monthly during the third intervention phase (booster phase) of 16 weeks * Phase D: two-monthly during the follow-up phase of 12 months

    Time frame: From baseline, throughout the intervention, to 12 months after end of treatment

  3. Reflective Functioning

    Reflective Functioning Questionnaire (RFQ): a 8 item self-report questionnaire. Outcome measures of the Single Case Experimental Design are assessed using a composite questionnaire that is delivered to participants repeatedly in varying frequencies depending on the phase of treatment and respective phase of the SCED. * Phase A: weekly during the baseline waiting period with a minimum of three weeks. * Phase B: bi-weekly during the first intervention phase of 10 weeks individual treatment and second intervention phase of 20 weeks group treatment * Phase C: monthly during the third intervention phase (booster phase) of 16 weeks * Phase D: two-monthly during the follow-up phase of 12 months

    Time frame: From baseline, throughout the intervention, to 12 months after end of treatment

  4. Treatment expectations

    Credibility and Expectancy Questionnaire (CEQ)

    Time frame: Baseline - after indication for treatment; End of treatment (end of phase C)

  5. Experiences of clients and clinicians

    Semi-structured interviews with clients and clinicians

    Time frame: End of phase C (booster phase)

07

Study locations

1 site
08

References and documents

Publications

  • Lemma A, Target M, Fonagy P. The development of a brief psychodynamic intervention (dynamic interpersonal therapy) and its application to depression: a pilot study. Psychiatry. 2011 Spring;74(1):41-8. doi: 10.1521/psyc.2011.74.1.41. PubMed 21463169 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2024 (actual). Primary completion is estimated for Oct 2027, 40 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2027, on Oct 20, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2024
First posted
Jun 24, 2024
StartActual
Jun 17, 2024
Primary completionEst.
Oct 2027was Jun 2026
CompletionEst.
Dec 2027
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 2026→Oct 2027
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Jun 2026→Oct 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06471010
Lead sponsor
De Viersprong
Collaborators
Stichting tot Steun, OnlinePsyhulp
Responsible party
Sponsor
First posted
Jun 24, 2024
Start date
Jun 17, 2024
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 20, 2026

Study contacts

Maaike L Smits, Dr.
principal investigator · De Viersprong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion